Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation : Liver Transplantation

Secondary Logo

Journal Logo

Advanced Search
Original Articles: MANAGEMENT OF CHRONIC LIVER DISEASE

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Younossi, Zobair M.*

Author Information

1Betty and Guy Beatty Center for Integrated Research, Inova Health SystemFalls ChurchVA

2Center for Liver Disease and Department of Medicine, Inova Fairfax HospitalFalls ChurchVA

*Address reprint requests to Zobair M. Younossi, M.D., M.P.H., F.A.A.S.L.D., Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA 22042. Telephone: 703‐776‐2540; FAX: 703‐776‐4386; E‐mail: [email protected]

Liver Transplantation 24(2):p 166-170, February 2018. | DOI: 10.1002/lt.25003

Abstract

Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%.1 Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States.2 As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.4 Therefore, the transplant team must be well versed in the state of current knowledge about NAFLD and transplant‐specific issues for this increasingly important indication for LT. Liver Transplantation 24 166–170 2018 AASLD.

© 2017 by the American Association for the Study of Liver Diseases.

Full Text Access for Subscribers:

AASLD members log in here
AASLD members log in here
AASLD members log in here

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid